One hepatitis delta virus player (HDV) has dropped out after Eiger Biopharmaceuticals Inc.’s phase III effort with peginterferon lambda turned up safety issues, while others remain busy in a space highlighted during last November’s meeting of the American Association for the Study of Liver Diseases. Shares of Palo Alto, Calif.-based Eiger (NASDAQ:EIGR) closed Sept. 13 at 41 cents, down 28 cents, or 40.6%, on word that the company is stopping the Limt-2 study in patients with chronic HDV.
The discontinuation of LIMT-2 was announced after 4 patients experienced hepatobiliary events resulting in liver decompensation during the phase 3 study of peginterferon lambda for HDV.
Eiger BioPharmaceuticals, Inc. (EIGR), a commercial-stage biopharmaceutical company focused on rare metabolic diseases, Wednesday said it has decided to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta or CHD.